Dados do Resumo

Título

Evaluation of the tumor suppressor role of miR-665 in papillary thyroid carcinoma

Introdução

Thyroid cancer (TC) is the most common endocrine cancer. Frequent mutations in papillary carcinomas include the BRAFT1799A point mutation and RET/PTC rearrangements. Dysregulation of microRNAs (miRNAs) also significantly impacts papillary thyroid carcinoma (PTC) development. Our previous studies found reduced expression of over 50 miRNAs from the DLK1-DIO3 region in human PTC samples. Bioinformatic analyses highlighted miR-665 as a key miRNA, potentially involved in PTC development and progression.

Objetivo

To evaluate the tumor-suppressive activity of miR-665 through in vitro functional assays.

Métodos

The PTC cell lines TPC-1 (carrying the RET/PTC1 oncogene) and BCPAP (carrying the BRAFT1799A point mutation) were transfected with a commercial miR-665 mimetic at concentrations of 10 nM and 20 nM. After transfection, these cells were evaluated in cell migration assays on boyden monolayers, also for proliferation and invasion assays. Cell lines transfected with transfection reagent alone served as controls.

Resultados

: Our data reveal that overexpression of miR-665 led to a reduction in migratory capacity (p<0.05) exclusively in the BCPAP cell line, which harbors the BRAF mutation. This effect was not observed in the TPC-1 cell line, which carries the RET/PTC1 oncogene.

Conclusões

Although further analysis is needed, our findings suggest that the impact of miR-665 on cell migration may vary depending on the type of oncogene present. Since BRAF-positive tumors tend to have a less differentiated and more aggressive phenotype compared to those with other MAPK signaling mutations, our results may pave the way for the development of new therapeutic strategies targeting these tumors.

Financiador do resumo

FAEPEX Project Number: Agreement 519.287
CAPES number: 88887.675682/2022-00

Palavras Chave

Thyroid Cancer; MicroRNA; therapeutics